Boston Scientific (BSX) Cost of Revenue (2009 - 2026)

Boston Scientific (BSX) has 18 years of Cost of Revenue data on file, last reported at $12.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 99.17% year-over-year to $12.0 million; the trailing twelve-month figure through Mar 2026 stood at $44.0 million (down 99.34% YoY), and the FY2025 full-year result was $46.0 million, down 99.12% from the prior year.
• Cost of Revenue climbed to $12.0 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $5.2 billion in Q4 2024 to a low of -$3.2 billion in Q4 2023.
• A 5-year average of $356.4 million and a median of $12.0 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 8566.67% in 2023 and sank 99.89% in 2025, its largest moves.
• Tracing BSX's Cost of Revenue over 5 years: stood at -$2.9 billion in 2022, then declined by 8.76% to -$3.2 billion in 2023, then soared by 266.02% to $5.2 billion in 2024, then slumped by 99.89% to $6.0 million in 2025, then surged by 100.0% to $12.0 million in 2026.
• Business Quant data shows BSX's Cost of Revenue at $12.0 million in Q1 2026, $6.0 million in Q4 2025, and $12.0 million in Q3 2025.